Peptide Alliance Blog
Education, industry news, and insights on peptide therapy and regenerative health
The Differentiation Wave: Why the Next Obesity Drugs Compete on Liver Health and Muscle Preservation, Not Just Weight Loss
The next wave of GLP-1 and multi-agonist drugs—including CagriSema, survodutide, and mazdutide—are competing on liver health, muscle preservation, and metabolic markers, not just weight-loss percentages.
Retatrutide's Phase 3 Enrollment and 2026 FDA Filing: The Triple-Agonist Obesity Drug Positioned to Surpass Tirzepatide
Eli Lilly's retatrutide produced 24.2% mean weight reduction in Phase 2—the largest ever for this class. With Phase 3 trials enrolling and a 2026 FDA filing guided, the triple-agonist is set to become the most effective obesity peptide on the market.
Beyond Tirzepatide: The Next-Generation Obesity Agonists Targeting Liver, Muscle, and Metabolism
A wave of dual and triple agonists—including cagrilintide, survodutide, and mazdutide—is advancing through trials, differentiating on liver health, muscle preservation, and dosing convenience rather than pounds lost alone.
Retatrutide Phase 3 Data and the FDA Filing Timeline: What the 2026 ADA Conference Revealed
Fresh data from the 2026 ADA conference strengthens the case for retatrutide as the next breakthrough in metabolic peptides, with Phase 3 trials advancing toward a late-2026 FDA submission.
Pentadecapeptide BPC-157 Stability Studies: What Current Research Reveals About Storage, Degradation, and Optimal Handling
Recent stability studies reveal critical insights into BPC-157 storage, degradation pathways, and handling protocols that maximize therapeutic potency and safety.
GLP-1 Long-Term Safety Data: What 5+ Years of Clinical Research Reveals About Semaglutide and Tirzepatide
Comprehensive analysis of 5+ years of clinical research on GLP-1 peptides (semaglutide, tirzepatide) reveals sustained cardiovascular benefits, manageable side effects, and important long-term safety considerations.
Peptide Bioavailability: Oral vs Injection Delivery Methods and Absorption Rates
A comprehensive analysis of peptide bioavailability across delivery methods, comparing oral vs injection absorption rates, exploring barriers to peptide uptake, and reviewing emerging technologies that may transform peptide administration.
BPC-157 Clinical Trials: Human Research, Safety Data, and What the Science Actually Shows
Examining the current state of BPC-157 human clinical trials, safety data, and evidence gaps between animal research and human applications.
Nasal Peptide Delivery: Intranasal Administration Methods, Bioavailability, and Clinical Applications
Comprehensive analysis of intranasal peptide delivery mechanisms, bioavailability data, clinical applications, and formulation strategies for nasal spray peptide administration.
Oral Peptide Delivery: The Future of Peptide Therapy Without Injections
Recent breakthroughs in oral peptide delivery systems are revolutionizing peptide therapy, eliminating the need for injections through advanced technologies like permeation enhancers, nanoparticle encapsulation, and smart delivery devices.
TB-500 vs BPC-157: Which Healing Peptide Is Right for You?
TB-500 and BPC-157 are both widely researched healing peptides, but they work through different mechanisms and have different strengths. This comparison breaks down the science behind each, when to use one vs. the other, and whether combining them makes sense.